Mid-treatment imaging useful for de-escalating therapy for oropharynx cancer
PHOENIX - A new phase II trial finds that PET scans obtained before and midway through treatment for p16-positive oropharynx cancer (OPC) can help determine whether a patient can receive a lower dose of radiation therapy in the second half of their treatment course without compromising cancer control. Patients in the trial who received de-escalated therapy experienced fewer short-term side effects than those who received standard therapy. Findings from the study will be presented today at the 2022 Multidisciplinary Head and Neck Cancers Symposium.
The study focused on imaging using fluorodeoxyglucose (FDG) to detect responses to chemoradiation for p16+ oropharynx cancer. While FDG is the most commonly used radiotracer in clinical PET imaging, this trial is the first to report its use as a mid-treatment imaging marker to guide de-escalation for OPC.
Patients in this multi-institution trial had FDG-PET scans to determine their metabolic tumor volume before and midway through treatment. The current analysis reports findings for the first 59 patients accrued to the trial. Those who had tumors with lower metabolic activity before treatment and more than 50% reduction in metabolic tumor volume after two weeks of treatment were de-escalated – specifically, treatment stopped at a total dose of 54 Gy in 27 fractions, rather than the standard total dose of 70 Gy in 35 fractions. All patients received concurrent weekly carboplatin/paclitaxel chemotherapy.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.